Toceranib

• Description :

  Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].

• Product Name Alternative :

  SU11654; PHA 291639E

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319

• Target :

  C-Kit; PDGFR; VEGFR

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Toceranib.html

• Purity :

  97.41

• Solubility :

  DMSO : 2.5 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

• Smiles :

  O=C(NCCN1CCCC1)C2=C(NC(/C=C3C(NC4=C\3C=C(C=C4)F)=O)=C2C)C

• Molecular Formula :

  C22H25FN4O2

• Molecular Weight :

  396.46

• Precautions :

  H315, H319

• References & Citations :

  [1]London CA, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003 Jul;9 (7) :2755-68.|[2]Halsey CH, et al. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia?) in canine mast cell tumor. BMC Vet Res. 2014 May 6;10:105.|[3]Mitchell L, et al. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med. 2012 Mar-Apr;26 (2) :355-62.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PDGFRβ; VEGFR2/KDR/Flk-1

• CAS Number :

  [356068-94-5]